Trial reportBMC endocrine disorders2026
The effect of dietary approaches to stop hypertension (DASH) diet on cardiometabolic and atherogenic indices in subjects with metabolic syndrome: a randomized clinical trial.
Trial report in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDietary approaches to stop hypertension (DASH) diet as a balanced dietary pattern is designed to help manage hypertension. The scientific evidence hypothesized that following the DASH diet may lead to reductions in cardiometabolic risk. We aimed to design a clinical trial to assess the impact of the DASH diet on cardiometabolic and atherogenic indices in individuals with metabolic syndrome (MetS).
methodsSixty participants diagnosed with MetS were randomly divided into two groups: the intervention group (adhering to DASH diet) or the control group (following a common healthy diet). Key outcomes of the present study including cardiometabolic index (CMI) as our primary outcome, and atherogenic index of plasma (AIP), atherogenic coefficient (AC) and castelli risk index II (CRI-II) as secondary outcomes were evaluated at the baseline and at the end of the study.
resultsWhile one participant excluded from the trial, 59 subjects completed the study. Baseline values of CMI (p = 0.33), AIP (p = 0.27), AC (p = 0.44) and CRI-II (p = 0.17) showed no significant difference between the intervention group and the control group. After adjusting for confounding factors, the intervention group demonstrated a significant decrease compared to the control group in CMI (−0.38±0.29 vs. −0.02±0.47; p = 0.001), AIP (−0.04±0.04 vs. 0.01 ± 0.07; p = 0.001), AC (−0.31±0.54 vs. 0.01 ± 0.72; p = 0.04) and CRI-II (−0.30±0.37 vs. −0.03±0.39; p = 0.009).
conclusionsAdherence to the DASH diet appears to be effective in reducing CMI and some atherogenic indices. Further well-designed clinical trials with longer intervention durations are needed.
trial registrationThe trial was registered on 21 October 2022 at Iranian Registry of Clinical Trials (IRCT20180201038585N12, https://irct.behdasht.gov.ir/trial/66161 ).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.